Eileen Shiuan Kathryn E Beckermann Alpaslan Ozgun Ciara Kelly Meredith McKean Jennifer McQuade Mary Ann Thompson Igor Puzanov John P Greer Suthee Rapisuwon Michael Postow Michael A Davies Zeynep Eroglu Douglas Johnson
10.1186/s40425-017-0210-0
J Immunother Cancer
2017 Feb 21;5:8.
ctla-4 checkpoint inhibitor immune thrombocytopenic purpura melanoma pd-1 thrombocytopenia
CC BY
https://pubmed.ncbi.nlm.nih.gov/28239462/
Antibodies, Monoclonal / adverse effects Antineoplastic Agents, Immunological / adverse effects CTLA-4 Antigen / antagonists & inhibitors Ipilimumab / adverse effects Programmed Cell Death 1 Receptor / antagonists & inhibitors Thrombocytopenia / chemically induced
Antibodies, Monoclonal / adverse effects Antineoplastic Agents, Immunological / adverse effects CTLA-4 Antigen / antagonists & inhibitors Ipilimumab / adverse effects Programmed Cell Death 1 Receptor / antagonists & inhibitors Thrombocytopenia / chemically induced Case Reports Antibodies, Monoclonal / therapeutic use Antineoplastic Agents, Immunological / therapeutic use Female Humans Ipilimumab / therapeutic use Melanoma / drug therapy Middle Aged Nivolumab Rituximab / therapeutic use Skin Neoplasms / drug therapy Thrombocytopenia / drug therapy Antibodies, Monoclonal Antineoplastic Agents, Immunological CTLA-4 Antigen CTLA4 protein, human Ipilimumab PDCD1 protein, human Programmed Cell Death 1 Receptor Nivolumab Rituximab
PMC5319013
28239462
Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy
2017